Loading stock data…
$3.02-0.02 (-0.82%)
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care.
MannKind Corporation in the Healthcare sector is trading at $3.06 with a market capitalization of $1.1B. Wall Street consensus targets $7.84 (8 analysts), implying a +156.8% move over the next 12 months. The stock is currently near its 52-week low of $2.23, remaining 21.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $109.38M↑ | $90.17M↓ | $111.95M↑ | $82.13M↑ | $76.53M |
| Gross Profit | $79.83M↑ | $72.70M↓ | $82.28M↑ | $61.93M↑ | $55.96M |
| Operating Income | -$835,000↑ | -$2.98M↑ | -$7.69M↓ | $18.78M↑ | $10.66M |
| Net Income | -$19.03M↓ | -$16.62M↓ | -$15.95M↓ | $7.99M↑ | $668,000 |
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary ...